(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 November 2022 (17.11.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/241148 A1

(51) International Patent Classification:
A61K 47/02 (2006.01) *A61P 11/00* (2006.01)
A61K 47/18 (2017.01) *A61P 29/00* (2006.01)
A61K 47/26 (2006.01) *A61P 35/00* (2006.01)
A61K 39/395 (2006.01) *A61P 37/00* (2006.01)
A61P 3/00 (2006.01)

(21) International Application Number:
PCT/US2022/029043

(22) International Filing Date:
12 May 2022 (12.05.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/187,476 12 May 2021 (12.05.2021) US

(71) Applicant: **ANAPTYSBIO, INC.** [US/US]; 10770 Wateridge Circle, Suite 210, San Diego, California 92121 (US).

(72) Inventors: **PRASEUTH, Alex**; 10770 Wateridge Circle, Suite 210, San Diego, California 92121 (US). **ZEN, Kevin**; 10770 Wateridge Circle, Suite 210, San Diego, California 92121 (US). **ALTOBELL III, Laurence**; 10770 Wateridge Circle, Suite 210, San Diego, California 92121 (US). **MARINO, Margaret H.**; 10770 Wateridge Circle, Suite 210, San Diego, California 92121 (US).

(74) Agent: **GASE, John L.**; Leydig, Voit & Mayer, Ltd., Two Prudential Plaza, Suite 4900, 180 N Stetson Avenue, Chicago, Illinois 60601 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ANTIBODY COMPOSITION

(57) Abstract: The invention relates to a stable liquid aqueous pharmaceutical formulation comprising an anti-interleukin 36 receptor (IL-36R) antibody or antigen binding antibody fragment; a buffer; a stabilizer; and a surfactant, and methods of treating a subject with the pharmaceutical formulation.




FIG 1A




FIG 1B




FIG 1C




FIG 1D

WO 2022/241148 A1

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*